Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

BACKGROUND: Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy–refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit. METHODS: Tumour samples from a phase III clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonker, D J, Karapetis, C S, Harbison, C, O'Callaghan, C J, Tu, D, Simes, R J, Malone, D P, Langer, C, Tebbutt, N, Price, T J, Shapiro, J, Siu, L L, Wong, R P W, Bjarnason, G, Moore, M J, Zalcberg, J R, Khambata-Ford, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915121/
https://www.ncbi.nlm.nih.gov/pubmed/24335920
http://dx.doi.org/10.1038/bjc.2013.753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915121/
https://www.ncbi.nlm.nih.gov/pubmed/24335920
http://dx.doi.org/10.1038/bjc.2013.753

Ejemplares similares